000275835 001__ 275835
000275835 005__ 20250119000336.0
000275835 0247_ $$2doi$$a10.3390/diagnostics15010024
000275835 0247_ $$2pmid$$apmid:39795552
000275835 0247_ $$2pmc$$apmc:PMC11720076
000275835 0247_ $$2altmetric$$aaltmetric:173120140
000275835 037__ $$aDZNE-2025-00070
000275835 041__ $$aEnglish
000275835 082__ $$a610
000275835 1001_ $$0P:(DE-2719)9001286$$aHagen, Johannes$$b0
000275835 245__ $$aDiagnostic Efficacy of 123Iodo-Metaiodobenzylguanidine SPECT/CT in Cardiac vs. Neurological Diseases: A Comparative Study of Arrhythmogenic Right Ventricular Cardiomyopathy and α-Synucleinopathies.
000275835 260__ $$aBasel$$bMDPI$$c2025
000275835 3367_ $$2DRIVER$$aarticle
000275835 3367_ $$2DataCite$$aOutput Types/Journal article
000275835 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1736946096_31493
000275835 3367_ $$2BibTeX$$aARTICLE
000275835 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000275835 3367_ $$00$$2EndNote$$aJournal Article
000275835 520__ $$aBackground/Objectives: 123Iodo-metaiodobenzylguanidine single photon emission computed tomography/computed tomography (123I-MIBG SPECT/CT) is used to evaluate the cardiac sympathetic nervous system in cardiac diseases such as arrhythmogenic right ventricular cardiomyopathy (ARVC) and α-synucleinopathies such as Parkinson's diseases. A common feature of these diseases is denervation. We aimed to compare quantitative and semi-quantitative cardiac sympathetic innervation using 123I-MIBG imaging of ARVC and α-synucleinopathies. Methods: Cardiac innervation was assessed using 123I-MIBG SPECT/CT in 20 patients diagnosed with definite ARVC and 8 patients with clinically diagnosed α-synucleinopathies. Heart-to-mediastinum-ratio (H/M-ratio), as semi-quantitative, was evaluated. Additionally, standardized uptake value (SUV), as quantitative, was measured as SUVmedian, SUVmax, and SUVpeak in the left ventricle (LV), the right ventricle (RV), and in the global heart, based on a CT scan following quantitative image reconstruction. Results: The quantification of 123I-MIBG uptake in the LV, the RV, and the global heart was feasible in patients suffering from α-synucleinopathies. SUVmedian, and SUVpeak demonstrated a significant difference between ARVC and α-synucleinopathies across all regions, with the α-synucleinopathy group showing a lower uptake. In addition, the H/M ratio showed significantly lower uptake in patients with α-synucleinopathies than in patients with ARVC. Conclusions: Patients with α-synucleinopathies demonstrate significantly lower cardiac innervation in semi-quantitative and quantitative examinations than ARVC patients. The comparison of semi-quantitative and quantitative examinations suggests that quantitative examination offers an advantage. Quantitative analysis can be performed separately for the LV, RV, and global heart. However, analyzing the LV or RV does not provide additional benefit over analyzing the global heart in distinguishing between α-synucleinopathies and ARVC. Considering the different clinical manifestations of these two diseases, the absolute SUV values should not be generalized across different pathologies, and disease-specific ranges should be used instead.
000275835 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000275835 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x1
000275835 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000275835 650_7 $$2Other$$a123I-MIBG
000275835 650_7 $$2Other$$aARVC
000275835 650_7 $$2Other$$aRV
000275835 650_7 $$2Other$$aSUV
000275835 650_7 $$2Other$$aheart
000275835 650_7 $$2Other$$aα-synucleinopathies
000275835 7001_ $$0P:(DE-2719)9001444$$aScheifele, Maximilian$$b1
000275835 7001_ $$aZacherl, Mathias J$$b2
000275835 7001_ $$0P:(DE-2719)9001160$$aKatzdobler, Sabrina$$b3$$udzne
000275835 7001_ $$0P:(DE-2719)9002620$$aBernhardt, Alexander$$b4$$udzne
000275835 7001_ $$0P:(DE-2719)9001539$$aBrendel, Matthias$$b5$$udzne
000275835 7001_ $$0P:(DE-2719)2811659$$aLevin, Johannes$$b6
000275835 7001_ $$0P:(DE-2719)2811373$$aHöglinger, Günter U$$b7$$udzne
000275835 7001_ $$00000-0002-5675-6128$$aClauß, Sebastian$$b8
000275835 7001_ $$aKääb, Stefan$$b9
000275835 7001_ $$00000-0003-1504-6565$$aTodica, Andrei$$b10
000275835 7001_ $$00000-0003-0986-2929$$aBoening, Guido$$b11
000275835 7001_ $$00000-0001-9172-3316$$aFischer, Maximilian$$b12
000275835 773__ $$0PERI:(DE-600)2662336-5$$a10.3390/diagnostics15010024$$gVol. 15, no. 1, p. 24 -$$n1$$p24$$tDiagnostics$$v15$$x2075-4418$$y2025
000275835 8564_ $$uhttps://pub.dzne.de/record/275835/files/DZNE-2025-00070%20SUP.zip
000275835 8564_ $$uhttps://pub.dzne.de/record/275835/files/DZNE-2025-00070.pdf$$yOpenAccess
000275835 8564_ $$uhttps://pub.dzne.de/record/275835/files/DZNE-2025-00070.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000275835 909CO $$ooai:pub.dzne.de:275835$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000275835 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001160$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000275835 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002620$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000275835 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001539$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000275835 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811659$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000275835 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811373$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000275835 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000275835 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x1
000275835 9141_ $$y2025
000275835 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-07
000275835 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-07
000275835 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000275835 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-01-07
000275835 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bDIAGNOSTICS : 2022$$d2025-01-07
000275835 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-08-29T10:48:13Z
000275835 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-08-29T10:48:13Z
000275835 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-07
000275835 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2025-01-07
000275835 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-07
000275835 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2025-01-07
000275835 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000275835 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-01-07
000275835 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2025-01-07
000275835 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-07
000275835 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-07
000275835 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-07
000275835 9201_ $$0I:(DE-2719)1111015$$kClinical Research (Munich)$$lClinical Research (Munich)$$x0
000275835 9201_ $$0I:(DE-2719)1110007$$kAG Haass$$lMolecular Neurodegeneration$$x1
000275835 9201_ $$0I:(DE-2719)1111016$$kAG Levin$$lClinical Neurodegeneration$$x2
000275835 980__ $$ajournal
000275835 980__ $$aVDB
000275835 980__ $$aUNRESTRICTED
000275835 980__ $$aI:(DE-2719)1111015
000275835 980__ $$aI:(DE-2719)1110007
000275835 980__ $$aI:(DE-2719)1111016
000275835 9801_ $$aFullTexts